IDH2

Across TCGA pan-cancer cohorts, IDH2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated IDH2 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher IDH2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated IDH2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUAD show a favorable association.

CCRCC, HNSC, and PDAC are the cancer types where IDH2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	IV	0.233	1.000	.008	18	view →
HNSC	OS	Tertile	All	0.930	1.000	.018	14	view →
PDAC	OS	Median	III,IV	0.455	0.967	.004	8	view →
UCEC	DFS	Tertile	II,III,IV	0.916	0.489	.035	4	view →
LUAD	OS	Quartile	All	0.664	0.243	.008	2	view →
LSCC	OS	Tertile	III,IV	0.993	0.578	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

IDH2–CCRCC (DFS)

Open the CCRCC breakdown →